How has been the historical performance of the Solara Active PP?

No Data Available for this Stock

how big is Solara Active PP?

As of June 06, Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 389.00 Cr, categorizing it as a Micro Cap. There is no available financial data for the latest four quarters or balance sheet information.

Market Cap: As of June 06, Solara Active Pharma Sciences Ltd Partly Paidup has a market capitalization of 389.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: As of June 06, there is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: As of June 06, there is no valid Consolidated or Standalone balance sheet data available, including values for Shareholder's Funds and Total Assets for the latest annual period.

When is the next results date for Solara Active PP?

No Upcoming Board Meetings

Has Solara Active PP declared dividend?

No Dividend History Available

What is the technical trend for Solara Active PP?

As of June 4, 2025, Solara Active PP shows a neutral trend with a slight bullish inclination due to a mildly bullish weekly MACD and RSI, despite daily moving averages being mildly bearish and no clear trend from Dow Theory and OBV.

As of 4 June 2025, the technical trend for Solara Active PP has changed from mildly bearish to sideways. The weekly MACD is mildly bullish, and the RSI is bullish, indicating some positive momentum in the short term. However, daily moving averages are mildly bearish, suggesting caution. The Bollinger Bands on the weekly chart are also bullish, supporting the upward potential. Dow Theory and OBV show no clear trend in both weekly and monthly time frames, indicating a lack of strong directional movement. Overall, the current stance is neutral with a slight bullish inclination, driven primarily by the weekly MACD and RSI.

Who are the peers of the Solara Active PP?

Peers of Solara Active PP include Venus Remedies, Ind-Swift Labs, Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab, Nectar Lifesci, and Infinium Pharma. Jenburkt Pharma has the highest 1-year return at 47.73%, while Solara Active PP leads with 59.14%.

Peers: The peers of Solara Active PP are Venus Remedies, Ind-Swift Labs., Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab., Nectar Lifesci., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Infinium Pharma, while Average management risk is found at Venus Remedies, Jenburkt Pharma, Zim Laboratories, Albert David, Medicamen Biotec, and the rest. Below Average management risk is present at Ind-Swift Labs., Valiant Laborato, Brooks Lab., and Nectar Lifesci. Growth is rated as Excellent for Venus Remedies, Jenburkt Pharma, Albert David, Medicamen Biotec, and the rest show Below Average growth, including Ind-Swift Labs., Zim Laboratories, and Valiant Laborato. Infinium Pharma stands out with Good growth. Capital Structure is Excellent for Venus Remedies, Jenburkt Pharma, Albert David, Medicamen Biotec, and the rest, while Average is noted for Zim Laboratories, and Below Average for Ind-Swift Labs., Valiant Laborato, Brooks Lab., and Nectar Lifesci.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jenburkt Pharma at 47.73%, while Ind-Swift Labs. has the lowest at -26.31%. Solara Active PP's 1-year return of 59.14% is higher than both of these peers. Additionally, several peers, including Ind-Swift Labs., Albert David, Medicamen Biotec, Valiant Laborato, Brooks Lab., Nectar Lifesci., and Infinium Pharma, have negative six-month returns.

What does Solara Active PP do?

Solara Active Pharma Sciences Ltd Partly Paidup is a micro-cap company in the Pharmaceuticals & Biotechnology sector with no reported sales or profits. It has a market cap of INR 541 Cr and key metrics such as a P/E ratio and dividend yield of 0.00%.

Overview: <BR>Solara Active Pharma Sciences Ltd Partly Paidup operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. There are no reported sales or profit figures for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 541 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price-to-Book: 0.00<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

Which are the latest news on Solara Active PP?

Why is Solara Active PP falling/rising?

As of 03-Dec, Solara Active Pharma Sciences Ltd Partly Paidup's stock price has risen to 378.40, marking a 7.82% increase after a seven-day decline, indicating a potential trend reversal. Despite this short-term recovery, the stock has faced significant declines over the year, and trading activity remains erratic with reduced investor participation.

As of 03-Dec, Solara Active Pharma Sciences Ltd Partly Paidup is experiencing a rise in its stock price, currently at 378.40, which reflects an increase of 27.45 or 7.82%. This upward movement is notable as it comes after a period of seven consecutive days of decline, indicating a potential trend reversal. The stock opened with a significant gain of 6.62% today and reached an intraday high of Rs 385.85, which is an increase of 9.94%.<BR><BR>In terms of performance relative to the market, the stock has outperformed its sector by 7.83% today. However, it is important to note that the stock has had a challenging performance over longer periods, with a year-to-date decline of 9.04% and a one-year decline of 28.81%. Despite this, the current rise may be attributed to a short-term recovery following a prolonged downturn.<BR><BR>Additionally, the trading activity shows that the stock has been erratic, with no trades on three out of the last twenty days. The delivery volume has also seen a significant drop of 87.17% compared to the five-day average, indicating falling investor participation. Despite these challenges, the stock's current rise suggests a momentary recovery phase, possibly driven by short-term trading dynamics rather than a fundamental shift in investor sentiment.